Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PFE
PFIZER INC.
NYSE
$27.96
▼ DOWN 0.21% (-0.06)

KEY STATISTICS

Market Cap$159.36 B
52w High$28.75
52w Low$23.58
Dividend Yield7.08%
FrequencyQuarterly
P/E9.17
Volume27.16M
Shares Out.5.70B

COMPANY

LEADERSHIP

Albert Bourla
CHIEF EXECUTIVE
Albert Bourla

COMPENSATION 2026

Salary$1,800,000
Stock Awards$9,442,705
Incentive Plan Pay$5,400,000
All Other Comp.$1,940,441
Total$27,585,301

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 1, 1972
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
75,000

PRICE TARGET

Target High$31.00
Target Low$26.00
Target Median$27.50
Target Consensus$28.17

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$15.93B
NOV
3
TUE

SPLIT RECORD

DATETYPERATIO
2020-11-17Forward527:500
1999-07-01Forward3:1
1997-07-01Forward2:1
1995-07-03Forward2:1
1991-04-01Forward2:1
1983-07-01Forward2:1

PRICE

$27.96 ▼ DOWN 0.21% (−$0.06)
OVERLAYS
$27.82$27.90$27.979:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM27.96

About Pfizer Inc.

https://www.pfizer.com ↗

Pfizer Inc. is a global biopharmaceutical company that develops, manufactures, and markets medicines and vaccines across various therapeutic areas, collaborating with partners and serving diverse healthcare providers worldwide.

INDUSTRY

Drug Manufacturers - General

A PRODUCT PFIZER INC. IS KNOWN FOR

Padcev (enfortumab vedotin-ejfv)
Padcev (enfortumab vedotin-ejfv)

Padcev is a blockbuster antibody-drug conjugate for advanced bladder cancer, central to Pfizer’s oncology growth strategy after acquiring Seagen, driving significant revenue through innovative cancer treatments.

COMPETITORS

COMPETITOR
AZN COMPARE
BMY COMPARE
IBRX COMPARE
JNJ COMPARE
MRK COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Biopharma Segment$16.31B $30.58B ▲$14.16B ▼$14.66B ▲
Segment Reporting Reconciling Item Corporate Nonsegment$344M $688M ▲$289M ▼$373M ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$10.69B $17.49B ▲$8.73B ▼$8.86B ▲
Developed Rest Of World$3.7B $9.1B ▲$3.43B ▼$3.74B ▲
Emerging Markets$2.27B $4.68B ▲$2.29B ▼$2.43B ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
1,067
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.20% · 181.5M
XUS.TO
0.25% · 76.0M
SPY
0.24% · 69.8M
FDL
6.34% · 18.3M
SZNE
9.60% · 16.8M
TDIV.L
4.06% · 16.0M
RSP
0.21% · 7.4M
FNDX
0.73% · 7.2M
DFUV
0.82% · 4.6M
WLDL.L
0.98% · 4.4M
FHLC
2.18% · 2.7M
XDWH.L
1.85% · 2.7M
CGGO
0.59% · 2.5M
H4ZJ.SG
0.34% · 2.3M
DLN
0.89% · 2.0M
ZSP.TO
0.24% · 1.8M
NULV
1.61% · 1.6M
QYLD.L
4.00% · 1.3M
WRDUSW.SW
0.18% · 1.1M
SDOG
2.02% · 1.1M
SPYI
0.24% · 1.0M
FLCO
0.16% · 1.0M
AVUS
0.19% · 965.7K
FDV
2.45% · 796.1K
BBUS
0.24% · 785.9K
SIXH
2.75% · 587.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
4,303
TOP 12 OF 4,303 · RANKED BY POSITION SIZE
Metatron Capital Sicav Plc
5.61B sh · $2.28B
Vanguard Group Inc
541.3M sh · $13.48B
Blackrock, Inc.
529.7M sh · $12.75B
Blackrock Inc.
424.4M sh · $11.87B
State Street Corp
307.1M sh · $7.39B
Blackrock Institutional Trust Company, N.A.
167.5M sh · $5.44B
Geode Capital Management, LLC
135.3M sh · $3.25B
Fisher Asset Management, LLC
109.1M sh · $2.63B
Blackrock Fund Advisors
105.4M sh · $3.42B
Morgan Stanley
96.3M sh · $2.32B
Norges Bank
93.7M sh · $2.27B
State Farm Investment Management Corp
80.6M sh · $1.43M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity3
Return On Assets3
Debt To Equity1
Price To Earnings1
Price To Book3
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Ro Khanna
Ro Khanna
Purchase
2026-04-13
 Gilbert Cisneros
Gilbert Cisneros
Purchase
2026-02-10
SENATE TRADES
Susan M. Collins
Susan M. Collins
Purchase
2026-02-03
HOUSE TRADES
James French Hill
James French Hill
Sale (Full)
2025-12-31

INSIDER TRADES

★
OFFICER: EXECUTIVE VICE PRESIDENT
Guegan Cecile
— · 9.1K shares
2028-02-25
★
OFFICER: EXECUTIVE VICE PRESIDENT
Guegan Cecile
— · —
2026-08-17
★
OFFICER: EXECUTIVE VICE PRESIDENT
Guegan Cecile
— · 33.1K shares
2030-03-04
★
OFFICER: EXECUTIVE VICE PRESIDENT
Guegan Cecile
— · 15.7K shares
2031-03-03

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 5
BUY 3
OUTPERFORM 1
HOLD 1
SECTOR PERFORM 1
EQUAL WEIGHT 1
12 GRADES IN THE LAST 12 MONTHS
Guggenheim BUY BMO Capital OUTPERFORM B of A Securities NEUTRAL JP Morgan NEUTRAL HSBC HOLD Cantor Fitzgerald NEUTRAL RBC Capital SECTOR PERFORM Citigroup NEUTRAL

SECTORS PEERS

PEERPRICE
MRK$148.26COMPARE
AMGN$432.42COMPARE
NVO$45.61COMPARE
GILD$145.68COMPARE
DHR$216.07COMPARE
BMY$66.58COMPARE
SYK$330.69COMPARE
SNY$44.82COMPARE